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New Surgical Techniques and
Surgical Site Infections
Steven M. Gordon
Cleveland Clinic Foundation, Cleveland, Ohio, USA
Technologic advances in surgery include a trend toward less invasive procedures, driven by potential
benefits to patients and by health-care economics. These less invasive procedures provide infection control
personnel opportunities for direct involvement in outcomes measurement.
“Pray before surgery, but remember
 God will not alter a faulty incision.”
Arthur H. Keeney
The 21st century advancements in genetics, nanotechnol-
ogy (mechanical engineering on a molecular scale), and
robotics could revolutionize medical therapy and diagnostics.
I will review current and future directions of minimally invasive
surgery, with an emphasis on cardiac surgery, and surgical
site infections after minimally invasive valve procedures.
Minimally Invasive Surgery
Since the first endoscopic cholecystectomy was performed
in France in 1988, minimally invasive surgical techniques
have dramatically affected many surgical subspecialties,
driven by advances in port access and video instrumentation
and the desire to lessen incision pain and length of hospital
stay. Advances in laparoscopic kidney and adrenal surgery
now include 2-mm needle optics and instruments, which have
resulted in decreased postoperative illness and superior
cosmetic results (1). The challenge is to evaluate the safety
and efficacy of these new techniques as they are widely
introduced in the United States.
Minimally invasive cardiac surgery was predated by
innovations in general surgery and is increasingly applied to
cardiac procedures (30,000 worldwide in 1998). Coronary
artery bypass grafting (CABG) through a median sternotomy
incision with cardiopulmonary bypass support remains
standard because it provides the surgeon with good exposure,
a bloodless and motionless field, and myocardial protection,
with graft patency rates of 90% at 10 years (2). However,
cardiopulmonary bypass support may have adverse physi-
ologic consequences, including a 6% incidence of central
nervous system events (3).
There is no internationally accepted case definition for
minimally invasive cardiac surgery, but two approaches to
revascularization have been developed: the off-pump (beating
heart) CABG, or minimally invasive direct coronary artery
bypass (MIDCAB), and the endoscopic (port access technique)
CABG (HeartPort, Redwood City, CA) (4).
Coronary artery anastomosis on a beating heart was first
described by Kosselov in 1967 and has been modified with the
MIDCAB technique to an 8-cm right or left anterior
thoracotomy incision that allows direct visualization of the
beating heart through small incisions. The primary candidate
for this procedure is a patient with single anterior vessel
disease; an estimated 1 of 3 coronary revascularization
procedures (CABG or percutaneous coronary artery
angioplasty) meet this criterion. The technical constraints of
the MIDCAB procedure include a moving surgical field and a
turgid heart on which to perform grafting. Stabilizers to
control heart movement are used to facilitate anastomosis of
the target grafts during suturing.
The port-access operation involves a mini-thoracotomy (8
cm) on an arrested heart by using percutaneously inserted
endovascular occluder balloons in the ascending aorta. Unlike
port-access surgery in noncardiac surgical subspecialties,
almost all cardiac operations on adult patients are
reconstructions that are technically more demanding when
performed through an endoscope. In addition, the laparoscop-
ic approach with an insufflated peritoneum provides better
exposure than open techniques (5).
Surgical site infections after minimally invasive cardiac
surgery pose a challenge to the clinician. Physical findings of
sternal instability and sternal click of the median sternotomy
cannot be applied to many incisions used in minimally
invasive cardiac surgery (Figure 1). The initial experience of
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Figure 1. Surgical site infection following minimally invasive valve
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1,400 minimally invasive cardiac surgery procedures at the
Cleveland Clinic showed no significant difference in the
incidence of deep or superficial wound infections (Table).
An important quality indicator for minimally invasive
surgical procedures is the conversion rate to open procedures.
A surgeon’s decision to convert from a minimally invasive
procedure to an open procedure may be determined by poorly
defined anatomy or surgical complications. Conversion is not
necessarily a failure but may be used as a quality indicator,
and conversion rates for minimally invasive cardiac surgery
procedures have declined substantially with increasing
experience at our institution (Figure 2). The introduction of
any new surgical technique involves a learning curve, and
increased experience may be translated into reduced illness
and death. Examples of the relationship between surgeon-
specific volume and death associated with CABG procedures
have been published (6-8).
The association of outcome with case volume may not
depend on a single person but on the collective abilities of the
clinical team (9). High volumes may also reflect selection bias
by patient referrals to institutions and surgeons with good
outcomes. Health-care consumers are increasingly interested
in outcome measurements, and one consumer advocate group
(the Center for Medical Consumers) has compiled 1998 data
from the New York State Department of Health for 21 surgical
procedures, stratified by volume, hospital, and individual
practitioner (available at URL www.medicalconsumers.org).
Solid Organ Transplantation
The greatest challenge facing solid organ transplantation
in the United States is a shortage of donors, with
approximately three persons awaiting transplantation for
every organ donated. Organs from pigs may alleviate the
shortage, but the challenge of xenotransplantation is in
replacing xenogenic epitopes (antigens) recognized as foreign
by the immune system. An additional concern is trans-species
transmission of endogenous retroviruses from donor animals,
such as porcine endogenous retrovirus (PoERV). Two cases of
successful extracorporeal hepatic support with transgenic pig
livers have been reported with no evidence of human PoERV
infection at 5 and 185 months of follow-up (10).
Another alternative to cardiac allotransplantation is the
implantable ventricular assist device (11). The two types
approved by the U.S. Food and Drug Administration
(HeartMate left ventricular assist device, ThermoCardiosys-
tems, Woburn, MA, and the Novacor left ventricular assist
device, World Health, Inc., Oakland, CA) are both electrical
pulsatile devices, implanted through a median sternotomy
with an inflow cannula in the apex of the left ventricle and an
outflow tube anastomosed to the ascending aorta. A single
drive line containing the electrical cable and the atmospheric
air vent leads transcutaneously from the implanted pump to
an external power pack (Figure 3).
Recipients of implantable left ventricular assist devices
are vulnerable to device-related infections because the
extracorpeal drive line (13.5 mm to 15 mm in diameter)
breaches normal cutaneous defenses against infection,
providing a portal of entry for pathogens (12). The incidence of
infection increases with duration of ventricular assist device
support (a mean of 120 days for patients awaiting heart
transplantation at the Cleveland Clinic in 1999). As
recipients are often malnourished or debilitated, it is not
surprising that 32% of patients had a device-associated
infection and 55% had a hospital-associated bloodstream
infection during support (13). Patients with ventricular assist
devices commonly receive antibiotic therapy, both for
prophylaxis or treatment of infections and on an empiric
Table. Ratesa of surgical site infections in patients undergoing minimally
invasive compared with traditional open heart surgery, Cleveland Clinic
Foundation, 1996–98
Minimally
Traditional   invasive
 (n=9,633)  (n=1,400)    p value >0.05
Overall ratea 3.3 2.9     Not significant
Deep infection 1.7 1.9     Not significant
aper 100 procedures
Figure 3. Implantable left ventricular assist device.
Figure 2. Conversion rates to open procedures among patients
undergoing minimally invasive heart surgery, Cleveland Clinic
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basis. The use of antibiotics may lead to development of
infections with fungi and drug-resistant pathogens. Despite
these implications, infections associated with ventricular
assist devices do not preclude successful transplantation.
Strategies for prevention of infection in recipients will focus
on the drive line exit site until technical advances can achieve
a totally implantable device.
Future Directions: From Blood
and Guts to Bits and Bytes
Technologic advances are continually being brought into
the operating room with increasing use of robotics and
teleoperating systems and virtual environment, which is the
fusion of robotics and three-dimensional imaging technology.
One issue with laparoscopic surgery is control of the camera
(laparoscopic lens) while the surgeon operates. There may be
problems with second guessing where the surgeon wants the
camera lens directed; movement of the camera lens, leading to
iatrogenic complications; and the expense of additional
personnel. Voice activation of a surgical robotic assistant has
permitted single-surgeon thorascopic surgery (14). The
surgeon registers voice commands into a voice card, and the
thorascope is connected with a robotic arm. In a study of
human-assisted versus robotic-assisted surgeries, all proce-
dures were successfully completed with no difference in
operating times and no technical mishaps related to the robot.
Teleoperating systems and telesurgery allow the
operator to perform surgery from a remote site. A three-
dimensional camera is outfitted with tactile, auditory, and
proprioceptive feedback. This technology may provide a
means to treat patients in hazardous or distant environments
where evacuation is not feasible. NASA is planning to send
astronauts on a 3-year mission to Mars by 2020 and believes
an acute medical crisis is likely during such a voyage.
Biomedical space researchers are reviewing the creation of a
digitized virtual astronaut, a computerized representation of
the entire physiology, updated in real time by input from a
comprehensive bank of sensors (Groopman J. Medicine on
Mars. New Yorker, February 14, 2000). Any necessary
surgery would be performed by the flight surgeon, coached by
the virtual mentor and aided by robotics.
In summary, the operating room remains a dynamic
environment undergoing rapid change and innovation. The
challenge for infection control practitioners is to adopt a
facilitative (not passive or resistant) involvement in
measurement and data-tracking instruments (e.g., registries,
conversion rates, surgical site infection rates) and embrace
opportunities for comparison.
Dr. Gordon is hospital epidemiologist and infectious disease staff
physician at the Cleveland Clinic Foundation and former Epidemic In-
telligence Service Officer (class of 1987) in the Hospital Infections Pro-
gram, CDC.
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